A hot creek in California turned out to hold a record-breaking amoeba, a materials lab put on-off switches into tattoo ink, a surgeon in Connecticut went looking for tinnitus in a blood draw, and an engineer rebuilt the most expensive desk in diagnostics history out of trial exhibits. Four stories this week. Nobody had to prick a finger, which is more than Theranos could promise.
Table of Contents
🔥 Fire Amoeba Breaks the Eukaryote Heat Record
RESEARCH
For decades, 60°C was treated as the ceiling for complex cells, a limit held by some algae and fungi, with the previous amoeba record at 57°C. Last month a newly named species, Incendiamoeba cascadensis ("fire amoeba from the Cascades"), was reported dividing at 63°C in a Cell paper published September 22. That's three degrees, which in this field counts as a lot.
The work comes from Angela Oliverio's lab at Syracuse University (she's the corresponding author; doctoral student H. Beryl Rappaport is first author). Between 2023 and 2025 they sampled a tributary of Hot Springs Creek in Lassen Volcanic National Park, a stream that runs largely neutral in a park better known for acid. In the lab, a wheatberry grew the bacteria that fed the amoebae.
The record is earned in the methods: growth was tested at 17 temperatures from 30°C to 64°C, with four replicate flasks per temperature, tracked over seven days. Expansion microscopy then caught mitotic spindles in cells fixed at 63°C. Growth peaked at 55-57°C. The cells were still moving at 64°C. Above that, they formed cysts and could recover after 70°C but not after 80°C. Think of it as an athlete who sprints at 63, walks at 64, and curls into a sleeping bag past that.
The caveats are real. Every limit was measured in lab culture, not in the creek. The record also depends on definitions: the authors separate replication, motility, and survival, and only replication counts toward the 63°C. The protein-stability claims are AI-assisted predictions (TemBERTure, AlphaFold2), which the authors say only capture overall trends. Rutgers biologist Debashish Bhattacharya, who wasn't involved, told NPR it is "really hard to find a really cool exotic organism and actually turn it into something that has a major impact on other species".
Oliverio's own pitch, in Scientific American: "Well, your laundry detergent might be improved." Finally, a press line that undersells the work.
💡 Switchable Tattoos, Tested on One Leg
RESEARCH
The pitch in our inbox was tattoos that show up only under certain light. What the paper actually describes is subtler. PhotoTat is a set of three inks (blue, magenta, and yellow) made of PMMA nanoparticles loaded with diarylethene photochromes. They are nearly invisible at rest, color up under UV, and erase under white light. In other words, UV switches it on and it stays on for a while, rather than glowing only while the lamp is pointed at it.
The work comes from Carson Bruns's lab at CU Boulder, with co-authors Mollie Stockton, Emily Gardner, and Hyejin Kwon. It was published October 9 in the Cell Press journal Matter & Light and funded by NSF and CU Boulder's engineering college. According to Live Science, a 365-nanometer UV LED switches the pigments on in around two to three seconds, and the color lasts hours to days indoors. Chosen wavelengths can switch colors off one at a time, so the skin works a bit like a rewritable printer.
Now the fine print. The full multicolor images were made only in silicone practice skin and excised pig skin. The human data come from one participant, Bruns himself, who filled in fish-scale designs on his leg (Fitzpatrick type II skin, so darker skin is untested in people). The paper reports the blue dye fatigues within 10-100 switching cycles and leaves a permanent purple by-product. CU Boulder says the pigments still need medical testing before they are deemed safe for humans. Bruns also co-founded HYPRSKN, the startup that sells his earlier single-color Magic Ink, so commercial interest exists here.
The best-case use is gentle: radiotherapy alignment marks that stay invisible except at the clinic. Fish scales optional.
👂 Tinnitus in a Blood Draw? Not Yet
RESEARCH
"Finally, a biomarker for tinnitus" is how this one arrived. The real story is an association. Prestin is the motor protein that lets the cochlea's outer hair cells change length and amplify sound. A UConn Health team measured it in 41 people with chronic, bilateral tinnitus and 41 controls, alongside otoferlin, connexin 26, and stereocilin.
The case-control study appeared this summer in Otolaryngology–Head and Neck Surgery. First author is Patrick Adamczyk, and the corresponding author, Kourosh Parham, is a professor of surgery in UConn Health's otolaryngology division. Participants had hearing tests, wore noise dosimeters for a week, and gave blood for ELISA. Prestin was higher in the tinnitus group (P = .006), and the gap held after adjusting for noise, hearing loss, and age (P = .003). The other three proteins did not differ. Funding came from an American Tinnitus Association grant, and Parham's blood test is patented.
As for size: according to New Atlas, the difference was a mere 330 picograms per milliliter. New Atlas also reports the test wasn't accurate enough to diagnose anyone, and prestin didn't rise with symptom severity. That clashes with the university release, which quotes Parham saying prestin "gives us a clinical indication of how bad the tinnitus is." Prestin also isn't exclusive to the ear; it has turned up in the heart. And a separate group measuring prestin in patients found a hearing link in spinal fluid and called for clinically approved prestin assays before any diagnostic use.
To be fair, Parham himself urges replication, and an earlier study of 89 people pointed the same way. Call it a lead, not a lab test. The release talks about drug development; the data so far support a second study.
💉 Theranos World Lets You Sit at Holmes's Desk
NEWS
The needle-free blood draw devices we covered before at least shipped hardware. The newest Theranos artifact is a website. Theranos World lets you open Holmes's MacBook, scroll her iPhone, and "run" the Edison. Its own description says every text and email is real, from the trial, and "parsed by Extend."
It was built by Bo Lau, an engineer at the document-processing company Extend, who told Fast Company it took three days. There is even a clickable green juice. TechCrunch notes the site promotes Extend and a watch party for Nathan Fielder's Holmes documentary, "You Can See Everything."
How accurate is it? The documents come from trial exhibits, and per TechCrunch, the era details (home-button iPhone, OS X El Capitan on the MacBook Air) are pegged to 2016. The office itself is a reconstruction. We found no parody disclaimer on the landing page, only a note on the desk plugging an Extend fraud-detection product. So it is half archive, half ad, which suits a company that was famous for its pitch decks.
The reality behind it: Holmes was sentenced to 135 months in November 2022 for defrauding investors. Per Axios, a judge cut that to 123 months in March. She is scheduled to move to a halfway house in August 2027 and be released Feb. 22, 2030, and she has said she asked President Trump for clemency. The Edison, sadly, still runs only in a browser.
What links this week is the gap between a demonstration and a population. PhotoTat switches beautifully in pig skin and on one engineer's leg, and nobody else has worn it yet. Prestin separates 41 people from 41 people by a few hundred picograms, and can't yet tell you which group you're in. Theranos sold a demo as if it worked for everyone, then let a courtroom run the validation study.
The amoeba is the one that minds the gap: four flasks at every temperature, replication, motility, and survival each reported separately, and a plain admission that nobody has watched it divide in the creek. That's how you claim a record without overclaiming one.
Would you get a tattoo you could switch off for Thanksgiving? Hit reply, we read everything. And if you know someone who still has a Theranos pitch deck bookmarked, forward this along.
Keep questioning everything (especially single-subject tattoo trials),
P.S. We tried to measure our own tinnitus after editing this issue. The prestin assay is patented; the ringing is free.